Shattuck Labs/$STTK
1D1W1MYTD1Y5YMAX
Capital at risk
About Shattuck Labs
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
- Ticker
- $STTK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40
- Headquarters
- Austin, United States
- Website
- www.shattucklabs.com
Shattuck Labs Metrics
BasicAdvanced
$681M
-
-$0.50
1.11
-
Price and volume
Market cap
$681M
Beta
1.11
52-week high
$8.33
52-week low
$1.59
Average daily volume
829K
Financial strength
Current ratio
27.587
Quick ratio
26.944
Long term debt to equity
0.853
Total debt to equity
0.853
Profitability
EBITDA (TTM)
-52.14
Gross margin (TTM)
-3,823.90%
Net profit margin (TTM)
-5,256.80%
Operating margin (TTM)
-5,570.50%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-24.43%
Return on equity (TTM)
-39.21%
Valuation
Price to revenue (TTM)
712.487
Price to book
3.24
Price to tangible book (TTM)
3.24
Price to free cash flow (TTM)
-17.276
Free cash flow yield (TTM)
-5.79%
Free cash flow per share (TTM)
-0.393
Growth
Revenue change (TTM)
-66.63%
Earnings per share change (TTM)
-58.54%
3-year revenue growth (CAGR)
5.20%
3-year earnings per share growth (CAGR)
-38.67%
What the Analysts think about Shattuck Labs
Analyst ratings (Buy, Hold, Sell) for Shattuck Labs stock.
Analyst projections of the future price of Shattuck Labs stock.
Bulls say / Bears say
SL-325 Phase 1 trial enrollment completed with data showing favorable safety, tolerability, and no evidence of DR3 agonism, positioning the program for rapid advancement. (Reuters)
Phase 2B trial of SL-325 in patients with Crohn’s disease is on track to initiate in Q3 2026, moving the lead DR3 antagonist toward proof-of-concept studies. (Reuters)
With $90.4 million in cash and equivalents as of March 31, 2026, Shattuck’s balance sheet is expected to fund operations into 2029, providing runway for clinical milestones. (Reuters)
No revenue and widening net losses; reported zero revenue and a Q1 2026 net loss of $14.8 million, highlighting ongoing cash burn. (Reuters)
Antidrug antibodies were detected in 3.7% of participants in the SL-325 Phase 1 trial, indicating potential immunogenicity concerns ahead of pivotal studies. (Reuters)
Shares tumbled 5.6% in pre-market trading after the company priced a $75 million follow-on offering at a 6.3% discount to market, reflecting investor apprehension over dilution. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Shattuck Labs Financial Performance
Revenues and expenses
Shattuck Labs Earnings Performance
Company profitability
Upcoming events
No upcoming events
Shattuck Labs News
AllArticlesVideos
Funds containing Shattuck Labs
Fund name | Fund size | $STTK weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.